Impact of Tenofovir on Hepatitis Delta Virus Replication in the Swiss Human Immunodeficiency Virus Cohort Study
Open Access
- 11 February 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 64 (9) , 1275-1278
Abstract
We analyzed changes in hepatitis B virus and hepatitis delta virus (HDV) viral loads (VL) during tenofovir-containing antiretroviral therapy among patients with a replicating HDV infection in the Swiss HIV Cohort Study. Only 28.6% experienced a ≥2.0 log reduction in HDV RNA, and 14.3% had undetectable HDV VL within 5 years.Keywords
This publication has 18 references indexed in Scilit:
- Hepatitis delta-associated mortality in HIV/HBV-coinfected patientsJournal of Hepatology, 2017
- Higher rate of hepatitis events in patients with human immunodeficiency virus, hepatitis B, and hepatitis D genotype II infection: A cohort study in a medical center in southern TaiwanJournal of Microbiology, Immunology and Infection, 2015
- Pegylated interferon therapy of chronic hepatitis D: In need of revisionHepatology, 2014
- Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patientsAIDS, 2014
- Hepatitis Delta Is a Major Determinant of Liver Decompensation Events and Death in HIV-Infected PatientsClinical Infectious Diseases, 2014
- Peginterferon plus Adefovir versus Either Drug Alone for Hepatitis DeltaNew England Journal of Medicine, 2011
- Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferonJournal of Viral Hepatitis, 2008
- Impact of Hepatitis D Virus Infection on the Long-Term Outcomes of Patients with Hepatitis B Virus and HIV Coinfection in the Era of Highly Active Antiretroviral Therapy: A Matched Cohort StudyClinical Infectious Diseases, 2007
- Treatment of hepatitis DJournal of Viral Hepatitis, 2005
- Use of α-interferon in the treatment of chronic delta hepatitisJournal of Hepatology, 1991